Creative Biolabs, a leading services provider who is committed to providing high-quality services to promote the development of antibody-drug conjugates (ADCs) and other innovative targeted protein therapeutic agents, recently upgraded their advanced ADC technologies covering all crucial stages in ADC development.
"It is worth mentioning our DrugLnk synthesis platform to prepare customized linkers with unique structures. This special platform helps generate a successful ADC linker of >95% purity to facilitate antibody-drug conjugate (ADC) development projects. We can provide a variety of chemically versatile linker molecules, including cleavable linkers, non-cleavable linkers, and intermediate linker modules equipped with with good blood stability and highly specialized conjugation chemistry, such as SMCC"
https://www.creative-biolabs.com/adc/classify-adc-linkers-7.htm